Solid Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.3%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
-$1.77next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, and available-for-sale securities Quarterly380.7MTarget: Sufficient to fund operations into the first half of 2028
Number of participants dosed in INSPIRE DUCHENNE Phase 1/2 trial Quarterly47Target: Complete enrollment to support potential accelerated approval pathway
Number of participants dosed in FALCON Phase 1b trial Quarterly2Target: Complete enrollment of adults aged 18-40 with FA and cardiac hypertrophy
Watch Items
- SGT-003 FDA Accelerated Approval Pathway AlignmentTrigger: Receipt of formal guidance or feedback from FDA Type C/regulatory meetings in 2026Action: Evaluate clinical trial design adjustments and timeline to BLA submission
- SGT-212 Initial Clinical Data ReadoutTrigger: Release of initial safety and biomarker data expected by year-end 2026Action: Assess frataxin expression levels and safety profile to determine dose-escalation strategy
- SGT-501 First Participant DosingTrigger: Dosing of the first participant in the Phase 1b ARTEMIS trial (expected Q2 2026)Action: Monitor initial safety and tolerability profile of SGT-501 in CPVT patients
Research as of 19 Jun 2026